Considering the secretory characteristics of AKR1B10 and the spectrum of NAFLD ranging from NAFL to NASH to cirrhosis and HCC, we aimed to evaluate the feasibility of AKR1B10 as a blood biomarker of NASH and fibrosis with parallel analyses of other blood and imaging biomarkers. This evidence concerns the gene AKR1B10 and hepatocellular carcinoma.